Pioglitazone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Pioglitazone is an oral insulin-sensitising drug originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the Singapore licence records contain no approved indication text; this comes from the knowledge-graph indication data) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pioglitazone is a thiazolidinedione that acts on PPAR-gamma, and its efficacy in type 2 diabetes has been established through its insulin-sensitising effects.
Opsismodysplasia is a rare skeletal dysplasia caused by mutations in INPPL1 (SHIP2), a negative regulator of PI3K/insulin signalling. This gives a theoretical link to insulin signalling and PPAR-gamma biology. However, no trials or literature support it, and the mechanism has not been verified. At this stage the prediction cannot be considered supported.
Other top-ranked predictions are also supported only by model scores. They include focal stiff limb syndrome, classic stiff person syndrome, thiamine-responsive dysfunction syndrome, several localised lipodystrophies, pancreatic agenesis and autoimmune oophoritis. The lipodystrophies have a plausible PPAR-gamma adipogenesis rationale. The seven publications linked to pancreatic agenesis all concern thiazolidinediones in type 2 diabetes. They do not provide direct evidence for that disease, which lacks the beta-cell mass that pioglitazone would act on.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12441P | ACTOS TABLET 15 mg | Tablet | Not stated in licence record |
| SIN12442P | ACTOS TABLET 30 mg | Tablet | Not stated in licence record |
| SIN16882P | DECULIN TABLET 30MG | Tablet | Not stated in licence record |
All three registrations are valid single-ingredient oral products.
Safety Considerations
- Disease-related cautions from the knowledge graph (these are graph-based contraindication links, not package insert text): kidney disease, liver disease, gallbladder disease, congestive heart failure, adrenocortical insufficiency (including Addison disease), pituitary hormone deficiencies (including hypopituitarism and Sheehan syndrome), hypogonadotropic hypogonadism (including Kallmann syndrome), thymus gland disease and infectious disease.
- Drug Interactions: 100 interactions were identified; the 20 reviewed here are mostly Moderate, with some Minor. Moderate examples include abiraterone, acetazolamide, hydrochlorothiazide, hydrocortisone, epinephrine, salbutamol, formoterol, phenylephrine, pseudoephedrine, alpelisib and ethanol. Minor examples include nifedipine, ethinylestradiol and lipoic acid.
Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (L5). There are no clinical trials or publications for opsismodysplasia, and the mechanistic link is theoretical. The package insert safety data has not been obtained.
To proceed, the following is needed:
- Mechanism of action data (MOA) from DrugBank
- Package insert warnings and contraindications from the HSA website
- Preclinical or mechanistic studies linking PPAR-gamma agonism and INPPL1/SHIP2 signalling to skeletal development
- Case reports or clinical studies in opsismodysplasia, or a re-evaluation of lower-ranked predictions with more plausible mechanisms (such as the lipodystrophies)
- A safety assessment for use in children and in patients with heart failure, liver or kidney disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.